ADMA Biologics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsADMA Biologics is a U.S. commercial biopharmaceutical company manufacturing and marketing FDA-approved plasma-derived immunoglobulins for immunodeficient patients.
What they do
ADMA operates two segments: ADMA BioManufacturing produces and sells three FDA-approved products—ASCENIV, BIVIGAM, and Nabi-HB—using its Boca Raton, Florida plasma fractionation facility (up to 600,000 liters annual capacity). ADMA BioCenters operates seven FDA-licensed source plasma collection centers in the U.S., supplying plasma for its own products and selling excess plasma to third parties. The company also sells intermediate by-products and provides occasional contract manufacturing and laboratory services.
Revenue drivers
- ASCENIV — IVIG for primary humoral immunodeficiency; drove 2Q 2026 revenue of $102.9M, up 24% year-over-year, and is the principal growth driver.
- BIVIGAM — IVIG for PI in adults and children 2+; revenue is stabilizing sequentially after facing competitive pricing pressure; smaller than ASCENIV.
- Nabi-HB — Hepatitis B immune globulin for acute exposure; marketed but not a primary growth contributor.
- Plasma sales and services — Sells source/hyperimmune plasma to third parties and provides contract manufacturing/lab services; smaller ancillary revenue.
Recent performance
2Q 2026 total revenue was $124.4M, up 2% year-over-year; ASCENIV revenue grew 24% to $102.9M. GAAP net income was $37.8M (up 11%), adjusted net income $39.0M (up 8%), and adjusted EBITDA $61.8M (up 22%). FY2025 revenue was $510.2M with GAAP net income of $146.9M, down from $197.7M in 2024. The balance sheet is strong: $136.0M cash, $192.8M long-term debt, and $408.2M equity as of 6/30/2026.
Strategy
Management is focused on driving ASCENIV adoption through real-world evidence, including an ACAAI abstract submission showing reduced hospitalizations and antibiotic use in 127 patients. They are expanding capacity and yield: a 2025 FDA-approved Prior Approval Supplement boosts ASCENIV and BIVIGAM yields by 20%+ from the same plasma volume. They are developing SG-001, a S. pneumoniae hyperimmune globulin, with a pre-IND package expected in FY2026 and a possible CNPV voucher to accelerate review. Guidance for FY2026 revenue is $530-560M, with adjusted net income of $170-200M and adjusted EBITDA of $265-300M.
Risks
- Profitability sustainability — Despite GAAP profits in 2024 and 2025, management cautions that future profitability and positive cash flow are not guaranteed.
- Third-party dependence — Relies on third parties for fill-finish, packaging, testing, and external source plasma, which could cause delays or shortages.
- Regulatory inspection exposure — Both segments and suppliers face FDA/other regulator inspections that could result in citations or enforcement actions.
- Competitive pricing pressure — The U.S. IG market is competitive with persistent pricing pressure, which has impacted BIVIGAM and may pressure overall margins.
Outlook
Management reiterates FY2026 guidance of $530-560M revenue, $170-200M adjusted net income, and $265-300M adjusted EBITDA. ASCENIV is expected to remain the primary growth driver with accelerating demand and expanding real-world evidence. BIVIGAM is expected to stabilize sequentially. SG-001 development continues with a pre-IND submission planned for FY2026.